ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Carbidopa

Also written as “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, “Levodopa-carbidopa intestinal gel” and “Carbidopa/levodopa/entacapone”.

Its studies are mostly in Parkinson Disease · Dyskinesias · Attention Deficit Disorder with Hyperactivity · Fibromyalgia · Disruptive, Impulse Control, and Conduct Disorders, led by 7 companies.

Drug pageCarbidopa: every studyMany companies study it; this page follows only the 21 they lead. All 55 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 30, 200521 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only80 open or runningphase 4since Jun 30, 2005Dec 10, 2004none ahead
AbbVieits history only60 open or runningphase 3since Jun 8, 2006Jun 8, 2006none ahead
Orion Corporation, Orion Pharmaits history only30 open or runningphase 2since Feb 14, 2011Jun 5, 2008none ahead
Amneal Pharmaceuticalsits history only10 open or runningphase 1since Nov 30, 2023Nov 30, 2023none ahead
Osmotica Pharmaceutical USits history only10 open or runningphase 2since Nov 12, 2007Nov 12, 2007none ahead
Shanghai WD Pharmaceuticalits history only10 open or runningphase 1since Feb 12, 2026Feb 12, 2026none ahead
SynAgile10 open or runningphase 2since Feb 22, 2021Feb 22, 2021none ahead

Also a collaborator on its studies: TFS Trial Form Support and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 22, 2021First study: phase 2 study in Parkinson DiseaseFirst studyNCT04778176 · 17 enrolled · Italy, Luxembourg, Spain

TargetBeta

DDC →read by rule
“DOPA decarboxylase inhibitor”ChEMBL 37, by rule

Other programs on DDC

ProgramCompanyFurthest phaseStudies
benserazide, levodopa drug combinationruleBial - Portela Cphase 13

Studies

The one study SynAgile leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04778176Parkinson Disease · Italy, Luxembourg, Spain2CompletedJul 21, 202217

How it is read

Names in the registry

  • “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, 3 entries
  • “Levodopa-carbidopa intestinal gel”, 3 entries
  • “Carbidopa/levodopa/entacapone”, 3 entries
  • “Levodopa-Carbidopa Intestinal Gel”, 2 entries
  • “Carbidopa”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.